Overview

Benefits of Trimetazidine in MAFLD Pateints

Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MAFLD
Phase:
Phase 2
Details
Lead Sponsor:
October 6 University
Treatments:
Furosemide
Hypoglycemic Agents
Niacin
Nicotinic Acids
Trimetazidine